SCHEMBL7187988

SCHEMBL7187988

COc1ccc(C(=O)/C=C/c2cccc([N+](=O)[O-])c2)c(OC)c1OC

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TXNRD1 Q16881 1/20 0.65
TXNRD3 Q86VQ6 1/20 0.65
TXNRD2 Q9NNW7 1/20 0.65
LMNA P02545 4/20 0.62
MAPT P10636 4/20 0.62
ALDH1A1 P00352 3/20 0.62
HTT P42858 2/20 0.62
TUBB1 Q9H4B7 3/20 0.62
HSP90AA1 P07900 3/20 0.61
CCR6 P51684 1/20 0.61
CYP1A1 P04798 1/20 0.58
CYP1A2 P05177 1/20 0.58
CYP1B1 Q16678 1/20 0.58
NTSR1 P30989 1/20 0.58
TDP1 Q9NUW8 1/20 0.58
MCL1 Q07820 2/20 0.57
TRPV1 Q8NER1 1/20 0.57
MAOB P27338 1/20 0.56
ABCB1 P08183 1/20 0.54
KRAS P01116 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7187991 1.00 TXNRD1 (0.65) TXNRD1TXNRD3TXNRD2LMNAMAPT
SCHEMBL8155105 1.00 TXNRD1 (0.65) TXNRD1TXNRD3TXNRD2LMNAMAPT
SCHEMBL15807306 0.89 TXNRD1 (0.59) TXNRD1TXNRD3TXNRD2LMNAMAPT
SCHEMBL14306020 0.86 KRAS (0.68) LMNAMAPTALDH1A1HTTTUBB1
SCHEMBL15807367 0.85 TXNRD1 (0.67) TXNRD1TXNRD3TXNRD2LMNAMAPT
SCHEMBL14306018 0.85 HSP90AA1 (0.79) TXNRD1TXNRD3TXNRD2LMNAMAPT
SCHEMBL14315261 0.84 TXNRD1 (0.76) TXNRD1TXNRD3TXNRD2LMNAMAPT
SCHEMBL15807351 0.84 TXNRD1 (0.65) TXNRD1TXNRD3TXNRD2LMNAMAPT
SCHEMBL14325796 0.84 TXNRD1 (0.72) TXNRD1TXNRD3TXNRD2LMNAMAPT
SCHEMBL14318108 0.84 MAPT (0.79) TXNRD1TXNRD3TXNRD2LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3333153-A1 NUCLEAR RECEPTOR MODULATORS AND THEIR USE FOR THE TREATMENT AND PREVENTION OF CANCER The U.S.A. as represented by the Secretary, Department of Health and Human Services (US) 2018-06-13 EP disclosed
US-20140171503-A1 NUCLEAR RECEPTOR MODULATORS AND THEIR USE FOR THE TREATMENT AND PREVENTION OF CANCER HUMAN SERVICES (US) 2014-06-19 US disclosed
US-20030065039-A1 Biologically active 1,3-bis-aromatic-prop-2-en-1-ones, 1,3-bis-aromatic-propan-1-ones, and 1,3-bis-aromatic-prop-2-yn-1-ones STATENS SERUM INSTITUTE (DK) 2003-04-03 US disclosed
EP-0996432-A2 BIOLOGICALLY ACTIVE 1,3-BIS-AROMATIC-PROP-2-EN-1-ONES, 1,3-BIS-AROMATIC-PROPAN-1-ONES, AND 1,3-BIS-AROMATIC-PROP-2-YN-1-ONES STATENS SERUMINSTITUT (DK) 2000-05-03 EP disclosed
WO-1999000114-A2 BIOLOGICALLY ACTIVE 1,3-BIS-AROMATIC-PROP-2-EN-1-ONES, 1,3-BIS-AROMATIC-PROPAN-1-ONES, AND 1,3-BIS-AROMATIC-PROP-2-YN-1-ONES STATENS SERUM INSTITUT (DK) 1999-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030065039-A1 Biologically active 1,3-bis-aromatic-prop-2-en-1-ones, 1,3-bis-aromatic-propan-1-ones, and 1,3-bis-aromatic-prop-2-yn-1-ones AKR1C3, AKR1C1, AKR1A1 TXNRD1 1169/4885TXNRD3 1918/4885TXNRD2 1770/4885
US-20140171503-A1 NUCLEAR RECEPTOR MODULATORS AND THEIR USE FOR THE TREATMENT AND PREVENTION OF CANCER AR, NCOA1, NR5A1 TXNRD1 474/4885TXNRD3 270/4885TXNRD2 707/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.